Abstract:Background: beta-Amyloid (A beta) fibrillation is critical for A beta deposition and cytotoxicity during the progression of Alzheimer's disease (AD). Consequently, anti-A beta monoclonal antibody drugs targeting A beta oligomers and aggregation are considered potential therapeutic strategies for AD treatment. Similar to the working mechanisms of anti-A beta monoclonal antibody drugs, our study identified osmundacetone (OAC), a small-molecule compound isolated from the traditional Chinese medicine Rhizoma Osmundae, as exerting anti-AD effects by targeting A beta. Purpose: This study sought to determine whether OAC influences the A beta burden in APP/PS1 mice and to identify potential regulatory mechanisms. Methods: Five-month-old APP/PS1 mice were injected intraperitoneally with OAC at a dose of 1 mg/kg for 12 weeks. The cognitive functions of the mice were assessed via the Morris water maze test and the open field test. Osmundacetone was analyzed via molecular docking, an isothermal dose-response fingerprint-cellular context thermal shift assay, a thioflavine T fluorescence assay, and an atomic force microscopy assay to analyze the effects of OAC on A beta fibrillation. Immunofluorescence, immunoblotting, and immunohistochemistry were used to assess A beta clearance, AD pathology, oxidative stress, and inflammatory responses. Results: The innovative biochemical and physical data illustrated that the ability of OAC to inhibit A beta fibrillation was accomplished by binding directly to A beta, which differed from the majority of previously reported natural polyphenols that modulate the A beta content and structure in an indirect manner. The inhibition of A beta fibrosis by OAC subsequently promoted A beta lysosomal degradation, resulting in a decreased A beta burden in APP/PS1 mice. Furthermore, OAC treatment inhibited oxidative damage by upregulating glutathione peroxidase expression and attenuated the production of inflammatory factors by downregulating nuclear factor-kB phosphorylation in APP/ PS1 mice. Conclusion: These findings demonstrate, for the first time, that OAC could reduce the brain A beta burden in APP/PS1 mice by inhibiting A beta fibrillation through direct binding to A beta and improve cognitive dysfunction by attenuating oxidative damage and neuroinflammation. These findings indicate that OAC may be a promising candidate for the treatment of AD.

Theranostic F-SLOH Mitigates Alzheimer's Disease Pathology Involving TFEB and Ameliorates Cognitive Functions in Alzheimer's Disease Models

Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models.

Molecular engineering of a theranostic molecule that detects Aβ plaques, inhibits Iowa and Dutch mutation Aβ self-aggregation and promotes lysosomal biogenesis for Alzheimer's disease

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease

Cognition-enhancing effect of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in the 5 x FAD transgenic mouse model of Alzheimer's pathology

Multifunctional Theranostic Carbazole-Based Cyanine for Real-Time Imaging of Amyloid-β and Therapeutic Treatment of Multiple Pathologies in Alzheimer's Disease

P1‐017: 12/15‐lipoxygenase Inhibition Reverses Cognitive Impairment, Amyloidosis, TAU and Synaptic Pathology by Stimulating Autophagy in the Brain of Aged 3XTG Mice

Combined targeting of pathways regulating synaptic formation and autophagy attenuates Alzheimer's disease pathology in mice

12/15-LIPOXYGENASE INHIBITION REVERSES COGNITIVE IMPAIRMENT, AMYLOIDOSIS, TAU AND SYNAPTIC PATHOLOGY BY STIMULATING AUTOPHAGY IN THE BRAIN OF AGED 3XTG MICE

Transferrin-Conjugated Melittin-Loaded L-Arginine-Coated Iron Oxide Nanoparticles for Mitigating Beta-Amyloid Pathology of the 5XFAD Mouse Brain

A small molecule transcription factor EB activator ameliorates beta‐amyloid precursor protein and Tau pathology in Alzheimer's disease models

Systemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer's disease.

Cognitive enhancement and neuroprotective effects of OABL, a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model

Superparamagnetic iron oxide nanoparticles conjugated with Aβ oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimer’s Disease

Selective Degradation of Hyperphosphorylated Tau by Proteolysis-Targeting Chimeras Ameliorates Cognitive Function in Alzheimer’s Disease Model Mice

FSTL1-knockdown Improves Neural Oscillation Via Decreasing Neuronal-Inflammation Regulating Apoptosis in Aβ1–42 Induced AD Model Mice

Osmundacetone Ameliorates Alzheimer's-like Pathologies by Inhibiting (3-Amyloid Fibrillation, Oxidative Damage and Neuroinflammation in APP/ PS1 Transgenic Mice

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

Oolonghomobisflavans from disaggregate tau fibrils across Alzheimer’s disease models